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Received May 9, 2013; accepted August 30, 2013AbstractBackground: It is unclear whether atrial fibrillation (AF) adversely influences the clinical course of patients with hepatocellular carcinoma
(HCC).
Methods: During the period from January 1, 2001 to December 31, 2010, 476 patients (mean  SD age 60.3  12.9 years) diagnosed with HCC
were retrospectively enrolled in our study. The HCC stage, treatment, baseline characteristics, underlying cardiovascular diseases, and corre-
sponding drug treatment were systematically reviewed. The primary endpoint was death from any cause.
Results: AF was associated with a significantly reduced survival time in patients with HCC (AF vs. non-AF patients mean  SD survival time
470.1  89.6 days vs. 1161.2  32.6 days, log-rank p < 0.001; probability of survival 0.20, 95% confidence interval 0.10e0.38, p < 0.001).
After adjustment for sex and age, AF was still associated with poorer survival times (hazard ratio 4.131, 95% confidence interval 2.134e5.733,
p < 0.001). The causes of death among 22 patients with both HCC and AF included 11 cases of hepatic failure, four cases of ruptured tumor, and
two cases of bleeding from esophageal varices. None of these patients with AF used warfarin. Seven bleeding events related to HCC were noted,
but none of these patients developed a major thromboembolism. The mean  SD follow-up period was 645  468 days.
Conclusion: Patients with HCC had a significantly reduced survival time with the comorbidity of AF. Tumor rupture was relatively common
among patients with both HCC and AF. The anticoagulation treatment of AF in patients with HCC deviated from the current guidelines without
an increase in thromboembolic events.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Atrial fibrillation (AF) is the most common form of
arrhythmia and has become a growing problem worldwide.1,2
The remaining lifetime risk for AF at age 40 years has been
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http://dx.doi.org/10.1016/j.jcma.2013.11.004have suggested that AF might complicate the clinical course
and outcome of patients with cancer during surgical or med-
ical treatment.
Hepatocellular carcinoma (HCC), which originates from
liver cells, has tripled in incidence in the past two decades and
has become the fastest rising cause of cancer-related death in
the USA; the hepatitis C virus (HCV) accounts for most
cases.3,4 It would therefore be expected that there will be
increasing numbers of patients with both HCC and AF, the
most prevalent arrhythmia. So far, the relationship between
arrhythmias and cancer has been somewhat overlooked.4 It
remains unclear whether AF is associated with different out-
comes for these patients. The aim of this study was tohinese Medical Association. All rights reserved.
Table 1
Baseline characteristics of groups of patients with hepatocellular carcinoma
with and without atrial fibrillation.
Parameters Patients with
both HCC and
AF (n ¼ 22)
Patients with
HCC without
AF (n ¼ 454)
p
Age (y) 75.9  10.1 59.5  12.6 <0.001
Male 15 (68.2) 349 (76.9) 0.495
DM 3 (13.6) 85 (18.7) 0.779
HTN 6 (27.3) 119 (26.2) 0.998
Clinical HF 1 (4.5) 19 (4.2) 1.000
Dyslipidemia 2 (9.1) 134 (29.5) 0.050
HBV 8 (36.4) 290 (63.9) 0.012
HCV 9 (40.9) 131 (28.9) 0.236
Alcohol use 2 (9.1) 70 (15.4) 0.554
Child score
No cirrhosis or A
B
C
12 (54.5)
9 (40.9)
1 (4.5)
303 (66.7)
102 (22.5)
49 (10.8)
0.121
BCLC stage
A
B
C
D, n (%)
3 (13.6)
4 (18.2)
11 (50.0)
4 (18.2)
126 (27.8)
142 (31.3)
118 (26.0)
68 (15.0)
0.062
Major vascular invasion 7 (31.8) 136 (30.0) 0.991
Extrahepatic spread 5 (22.7) 77 (17.0) 0.489
Treatment
Surgery
Locoregional therapy
5 (22.7)
12 (54.5)
169 (37.2)
247 (55.4)
0.157
0.957
Data are presented as mean  standard deviation or n (%).
AF ¼ atrial fibrillation; BCLC stage ¼ Barcelona Clinic Liver Cancer stage;
DM ¼ diabetes mellitus; HCC ¼ hepatocellular carcinoma; HF ¼ heart fail-
ure; HTN ¼ hypertension; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus.
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with HCC.
2. Methods
Patients with HCC in Taipei Veterans General Hospital were
retrospectively reviewed and a total of 476 patients with HCC
were recruited from January 2001 to December 2010. The
underlying viral hepatitis status, HCC stages, laboratory tests,
electrocardiography, and treatment choice of each patient were
meticulously scrutinized. All patients were followed up until
December 31, 2011. The primary endpoint was death due to all
causes to delineate the survival impact of AF on patients with
HCC. Thereafter the causes of death were analyzed further.
Diagnoses of HCC were confirmed based on the guidelines
proposed in 2005 by the American Association for the Study
of Liver Diseases. By these criteria, HCC is diagnosed if a
patient has one or more risk factors [hepatitis B (HBV) or C
(HCV) virus infection, or cirrhosis, or both] and one of the
following: a serum a-fetoprotein (AFP) level >200 ng/mL and
a positive result with at least one of the three typical imaging
techniques (triple-phase computed tomography, contrast-
enhanced dynamic magnetic resonance imaging, or hepatic
angiography); or a serum AFP level of <200 ng/mL and
positive findings with at least two of three imaging techniques.
A positive result for typical HCC through the use of dynamic
computed tomography or magnetic resonance imaging is
indicative of arterial enhancement followed by venous
washout in the delayed portal/venous phase.5 Any case of
HCC diagnosed before 2005 was confirmed by pathology
(either a biopsy or surgical sample).
AF was confirmed by surface 12-lead electrocardiography
performed by at least two cardiologists. The AF type was
evaluated for all patients by a review of their medical records,
with an extensive examination of all the electrocardiographic
results for each patient.
The medical records of enrolled patients were reviewed for
age, sex, HBV, or HCV infection status, history of alcoholism,
dyslipidemia (defined as total cholesterol >200 mg/dL or
triglyceride >150 mg/dL), diabetes mellitus, ChildePugh
score, chemistry profiles, AFP level, size and number of
tumor, extrahepatic spread of tumor, hepatic or portal vein
invasion by tumor, the presence of lymph nodes or distant
metastasis, and the Eastern Cooperative Oncology Group
performance status. Treatment modalities for HCC for each
patient were recorded, including surgery, locoregional treat-
ment (transarterial chemoembolization, percutaneous ethanol
injection, and radiofrequency ablation), radiotherapy, and
cytotoxic chemotherapy. The retrospective study was per-
formed without violating guidelines for clinical research.2.1. Statistical analysesThe two-sample t tests were used for noncategorical data.
Categorical data were compared using a Chi-square test with
Yates’ correction or Fisher’s exact test. The overall survival was
determined and compared using a KaplaneMeier analysis andlog-rank test. A Cox regression analysis was used to identify the
independent factors associated with mortality. Variables
selected for multivariate analysis had p < 0.1 on univariate
analysis and statistical significance was established if p < 0.05.
3. Results3.1. Baseline characteristicsTwenty-two patients with both HCC and AF were identified
and another 454 patients with HCC without AF were enrolled
from the same medical center database. The mean  SD
duration of follow-up was 645  468 days. The AF group was
older than the non-AF group (75.9  10.1 years versus
59.5  12.6 years, p < 0.001) with a lower incidence of HBV
infection (36.4% versus 63.9%, p ¼ 0.012). Sex, diabetes
mellitus, hypertension, dyslipidemia, HCV infection, alcohol
use, ChildePugh score and Barcelona Clinic Liver Cancer
(BCLC) staging system, major vascular invasion, extrahepatic
spread, and treatment strategies such as locoregional treatment
or surgery did not differ between the groups with and without
AF (Table 1).3.2. Characteristics of patients with AFThe clinical courses of all 22 patients with both HCC and
AF were carefully examined. All electrocardiographic data
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follow-up, or until death. Four (18.2%) patients with parox-
ysmal AF, three (13.6%) patients with persistent AF, and 15
(68.2%) patients with permanent AF were identified. None of
these patients was prescribed warfarin. Eleven (50%) of the
patients with AF were taking aspirin. One (4.5%), seven
(31.8%), 12 (54.6%), and two (9.1%) patients had CHADS2
scores of 4, 2, 1, and 0, respectively (Table 2).3.3. Association of AF and death from HCCFig. 1. KaplaneMeier analysis of overall survival in patients with hepato-
cellular carcinoma with or without atrial fibrillation and in elderly (>70 years
old) patients with hepatocellular carcinoma with or without atrial fibrillation.During a mean follow-up period of 21.5 months, 18 and
131 deaths were identified in the AF and non-AF group,
respectively. Using the log-rank test in the KaplaneMeier
analysis, the patients with both HCC and AF were associated
with a significantly shorter mean  SD survival time (AF
versus non-AF 470.1  89.6 days vs. 1161.2  32.6 days, log-
rank p < 0.001; Fig. 1). The relative ratio of survival for pa-
tients in the AF compared with the non-AF group was 0.20
(95% confidence interval (CI) 0.10e0.38, p < 0.00). Subse-
quent adjustment for sex and age showed a significantly poorer
outcome in the group with both HCC and AF: hazard ratio
(HR) for mortality 4.131, 95% CI 2.134e5.733, p < 0.001.
We also performed age subgroup analysis via stratification of
the age groups (Table 3). Significantly worse survival was
detected among all patients older than 70 years (HR for
mortality 7.306, 95% CI 3.75e14.23, p < 0.001, Fig. 1). The
main survival difference occurred in the group aged
70e80 years, in which those with both HCC and AF had a
significantly higher risk of death from all causes (HR 9.81,Table 2
Clinical characteristics of 22 patients with both hepatocellular carcinoma and atria
Patient no. Age (y) Sex HBV HCV BCLC
stage
HTN
1 79 F þ e C þ
2 42 M þ e D e
3 77 M e e D þ
4 80 M e e C e
5 81 M e e B þ
6 77 M e e B þ
7 86 F e þ A e
8 87 M e e D e
9 72 F e þ D e
10 83 F þ þ C e
11 70 F e þ C þ
12 85 M e þ C e
13 71 M þ e C e
14 76 M þ e C e
15 85 M þ e C e
16 85 F e þ B e
17 72 M þ e B þ
18 80 M e þ A e
19 65 M e þ C e
20 80 F e þ C e
21 72 M e e C e
22 64 M þ e A e
AF ¼ atrial fibrillation; BCLC stage ¼ Barcelona Clinic Liver Cancer stage; BS
EVB¼ esophageal variceal bleeding; F ¼ female sex; HCC ¼ hepatocellular carcin
L ¼ locoregional treatment; M ¼ male sex; MOF ¼ multiorgan failure; S ¼ surg95% CI 4.16e23.12, p < 0.001). Among patients older than
80 years of age, AF did not have a significant impact on
overall survival (HR 1.96, 95% CI 0.68e5.74, p ¼ 0.211).
Among patients younger than 70 years of age, no survival
difference was detected between groups.3.4. Treatment and outcome of patients with both HCC
and AFThe treatment modalities (surgery or locoregional treat-
ment) for HCC did not differ between the AF and non-AFl fibrillation.
DM CS Tx Endpoint Cause of death
þ 4 S þ L þ HCC, liver failure
þ 2 S þ L þ HCC, liver failure
e 2 BSC þ Tumor rupture with shock
þ 2 BSC þ HCC, liver failure
e 2 S þ L þ HCC, liver failure
e 2 S þ L þ HCC, liver failure
e 2 L þ Tumor rupture with shock
e 2 BSC e d
e 1 BSC þ HCC, liver failure
e 1 BSC þ Tumor rupture with shock
e 1 L þ HCC, liver failure
e 1 L þ HCC, liver failure
e 1 BSC þ EVB with shock, MOF
e 1 L þ HCC, liver failure
e 1 BSC þ Tumor rupture, MOF
e 1 L þ HCC, liver failure
e 1 L þ HCC, liver failure
e 1 L þ HCC, liver failure
e 1 L e d
e 1 BSC e
e 0 L þ EVB with shock, MOF
e 0 S þ L e
C ¼ best supportive care; CS ¼ CHADS2 score; DM ¼ diabetes mellitus;
oma; HTN ¼ hypertension; HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus;
ery; Tx ¼ treatment.
Table 3
Association between atrial fibrillation and all causes of death among patients
with hepatocellular carcinoma in different age groups.
AF HR 95% CI p
>80 1.96 0.68e5.74 0.211
70e80 9.81 4.16e23.12 <0.001
60e70 0.05 0 to >50 0.603
CI ¼ confidence interval; HR ¼ hazard ratio.
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with a CHADS2 score 2, 12 with a CHADS2 score ¼ 1, and
two patients with a CHADS2 score ¼ 0. None of the patients
was prescribed warfarin. Eleven patients received antiplatelet
drugs (50.0%). Rate control drugs, including beta blockers,
calcium channel blockers, and digoxin, and were prescribed in
12 patients (54.5%). One patient received amiodarone. The
treatment of patients with AF for thromboembolism was
clearly inadequate according to the 2006 American College of
Cardiology/American Heart Association guideline.6
The total death rate during follow-up in patients with AF
was 81.8% (n ¼ 18). The cause of death in the patients with
AF included 12 cases of hepatic failure, four cases of tumor
rupture, and two cases of bleeding from esophageal varices
(Table 2). Even when patients with BCLC stage D were
excluded, patients with both AF and HCC still had signifi-
cantly shorter survival times than patients with HCC but no
AF (log-rank p < 0.001). Thus AF influenced the survival of
those so-called relatively manageable patients with HCC
(BCLC stages A to C). None of the patients developed a
thromboembolic event despite an extremely low rate of use of
anticoagulant drugs.4. Discussion4.1. Main findingsThe present study shows that AFwas significantly associated
with a poor prognosis in patients with HCC, especially in older
patients. The use of anticoagulant drugs deviated from the
current guidelines. The causes of death in patients with AFwere
mostly attributed to hepatic failure and death from tumor rupture
was relatively higher among patients with both HCC and AF.4.2. Association between AF and survival in patients
with HCCIt is reasonable to expect that a patient with cancer will
have a poorer prognosis if he or she has another disorder of a
major organ. However, the mechanism through which AF acts
to influence the clinical outcome of patients with HCC is not
yet clear. The poorer survival among patients with both HCC
and AF may be ascribed to a higher risk of congestive heart
failure due to chronic rhythm incompetence. The majority of
patients with both AF and HCC died from hepatic failure
(61%). Tumor rupture is an uncommon complication of he-
patocellular carcinoma. However, we observed a relativehigher incidence of tumor rupture in patients with both AF and
HCC (18%). The probable explanation for this observation is
that AF predisposes a patient to intracardial thrombus for-
mation, and the microthrombi randomly embolize the systemic
microcirculation, including that of the HCC, which is artery-
dependent. Chronic embolization-related hypoxia may lead
to the activation of hypoxia inducible factor-1, which pro-
motes angiogenesis, invasion, and epithelial-mesenchymal
transition.7 Over-promotion of angiogenesis may lead to a
clinical picture of tumor rupture.4.3. Interaction between HCC and AFWhether or not cancer can induce AF remains an unsettled
question. In limited case control studies, cancer was not found
to lead to AF per se, but did lead to AF due to a high inflam-
mation state.8e11 AF, exacerbated by anticancer treatments,
was suspected to complicate the outcome of patients with
cancer during surgical or medical treatment. However, there is a
lack of clinical evidence for an association, especially for pa-
tients with HCC. The present study first showed that AF was
associated with a poorer prognosis in patients with HCC,
providing clinical evidence that links AF to clinical outcomes
in patients with HCC and implies that treating AF correctly
might help patients with HCC. In this study, no obvious cor-
relation was observed between the CHADS2 score and survival.4.4. Dilemma in the prevention of thromboembolism in
patients with AF and HCCThe maintenance of patients with AF depends partially on
atrial remodeling and gives rise to a predisposition to throm-
boembolism.12 The prevention of thromboembolism in pa-
tients with both AF and HCC is difficult, and current
American College of Cardiology/American Heart Association
guidelines have not yet been validated for patients with HCC.6
Commonly, patients with HCC are associated with thrombo-
cytopenia, making the standard guidelines for treatment with
anticoagulant drugs inapplicable. It remains unclear whether
these thromboembolism events would be similar in patients
with thrombocytopenia or in patients with HCC. The inter-
action between chemotherapeutic drugs and warfarin might
further prevent the benefit of anticoagulant drugs and
contrarily lead to a higher bleeding rate.
In the present study, the use of anticoagulant drugs is
discordant with the guideline, which reflects the dilemma in
the prevention of thromboembolism in patients with both AF
and HCC. None of the patients had, or died of, a major
thromboembolism, and most of the deaths could be attributed
to cancer. It is possible that most patients would die from
cancer before the development of a major thromboembolism.
These findings lead us to reconsider the necessity of using
anticoagulant drugs in this particular population. The profile of
risks and benefits might be different from the profiles of pa-
tients without malignancies. We need a larger number of pa-
tients with both HCC and AF to further elucidate the issue. It
is possible that AF might represent as a prognostic marker.
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AF could lead to different outcomes in these patients.4.5. LimitationsThe present study was limited by its retrospective, single-
center design as well as by the number of patients with AF
studied. A larger prospective cohort might be needed to confirm
our findings. The present study could not define the causality
between AF and death from HCC. Also, the data related to
heart failure, e.g. left ventricular ejection fraction or left atrium
size, did not exist for every patient. Thus no further relationship
between heart failure and outcome could be determined.
In conclusion, AF was associated with a significantly lower
probability of overall survival in patients with HCC, especially
elderly patients. Tumor rupture was relatively common among
patients with both HCC and AF. The anticoagulation treatment
ofAF in patientswithHCCdeviated from the current guidelines,
without increasing the incidence of thromboembolic events.
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